These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26808227)

  • 1. On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.
    Vauquelin G; Van Liefde I; Swinney DC
    Br J Pharmacol; 2016 Apr; 173(8):1268-85. PubMed ID: 26808227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-molecule force spectroscopy study of interactions between angiotensin II type 1 receptor and different biased ligands in living cells.
    Li W; Xu J; Kou X; Zhao R; Zhou W; Fang X
    Anal Bioanal Chem; 2018 May; 410(14):3275-3284. PubMed ID: 29492619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor.
    Kellici TF; Ntountaniotis D; Kritsi E; Zervou M; Zoumpoulakis P; Potamitis C; Durdagi S; Salmas RE; Ergun G; Gokdemir E; Halabalaki M; Gerothanassis IP; Liapakis G; Tzakos A; Mavromoustakos T
    Curr Med Chem; 2016; 23(1):36-59. PubMed ID: 26572611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
    Sallander J; Wallinder C; Hallberg A; Åqvist J; Gutiérrez-de-Terán H
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1355-9. PubMed ID: 26810314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
    Vanderheyden PML; Benachour N
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3621-3628. PubMed ID: 28666735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do all angiotensin II type 1 receptor blockers have the same beneficial effects?
    Miura S; Saku K
    Br J Pharmacol; 2007 Aug; 151(7):912-3. PubMed ID: 17572701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying structural features related to the biological activity of a series of AT1 antagonists from fragment-based drug design.
    da C Silva D; Maltarollo VG; Honorio KM
    Protein Pept Lett; 2014 Jun; 21(6):542-9. PubMed ID: 24779772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor.
    Takezako T; Unal H; Karnik SS; Node K
    Mol Pharmacol; 2015 Sep; 88(3):488-501. PubMed ID: 26121982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
    Wang JL; Zhang J; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
    Eur J Med Chem; 2012 Mar; 49():183-90. PubMed ID: 22309912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.
    Zhang J; Wang JL; Yu WF; Zhou ZM; Tao WC; Wang YC; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
    Eur J Med Chem; 2013 Nov; 69():44-54. PubMed ID: 24007859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trans and Cis Conformations of the Antihypertensive Drug Valsartan Respectively Lock the Inactive and Active-like States of Angiotensin II Type 1 Receptor: A Molecular Dynamics Study.
    Wang L; Yan F
    J Chem Inf Model; 2018 Oct; 58(10):2123-2130. PubMed ID: 30212210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor.
    Balakumar P; Jagadeesh G
    J Mol Endocrinol; 2014 Oct; 53(2):R71-92. PubMed ID: 25013233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
    Berellini G; Cruciani G; Mannhold R
    J Med Chem; 2005 Jun; 48(13):4389-99. PubMed ID: 15974591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II cyclic analogs as tools to investigate AT
    St-Pierre D; Cabana J; Holleran BJ; Besserer-Offroy É; Escher E; Guillemette G; Lavigne P; Leduc R
    Biochem Pharmacol; 2018 Aug; 154():104-117. PubMed ID: 29684376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives.
    Agelis G; Resvani A; Durdagi S; Spyridaki K; Tůmová T; Slaninová J; Giannopoulos P; Vlahakos D; Liapakis G; Mavromoustakos T; Matsoukas J
    Eur J Med Chem; 2012 Sep; 55():358-74. PubMed ID: 22889560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of CoMFA models of affinity and selectivity to angiotensin II type-1 and type-2 receptors.
    Sköld C; Karlén A
    J Mol Graph Model; 2007 Jul; 26(1):145-53. PubMed ID: 17161636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
    Le MT; Pugsley MK; Vauquelin G; Van Liefde I
    Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography.
    Zhang H; Unal H; Gati C; Han GW; Liu W; Zatsepin NA; James D; Wang D; Nelson G; Weierstall U; Sawaya MR; Xu Q; Messerschmidt M; Williams GJ; Boutet S; Yefanov OM; White TA; Wang C; Ishchenko A; Tirupula KC; Desnoyer R; Coe J; Conrad CE; Fromme P; Stevens RC; Katritch V; Karnik SS; Cherezov V
    Cell; 2015 May; 161(4):833-44. PubMed ID: 25913193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand binding determinants for angiotensin II type 1 receptor from computer simulations.
    Matsoukas MT; Cordomí A; Ríos S; Pardo L; Tselios T
    J Chem Inf Model; 2013 Nov; 53(11):2874-83. PubMed ID: 24090110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.
    Vauquelin G
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):949-62. PubMed ID: 23812645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.